‘Aggressive therapy’ key in axial spondyloarthritis despite lack of T2T recommendation

SAN DIEGO — Although current American College of Rheumatology guidelines eschew treat-to-target for axial spondyloarthritis, “aggressive treatment” is still needed to manage the disease, noted a speaker here.
“The 2019 ACR treatment guidelines say treat-to-target is not yet ready for prime time in axial spondyloarthritis,” Atul Deodhar, MDMRCP, of Oregon Health and Science University, told attendees at the Congress of Clinical Rheumatology West. “However, aggressive therapy is still important.”
Whether treating axial SpA or non-radiographic axial SpA,

SAN DIEGO — Although current American College of Rheumatology guidelines eschew treat-to-target for axial spondyloarthritis, “aggressive treatment” is still needed to manage the disease, noted a speaker here.
“The 2019 ACR treatment guidelines say treat-to-target is not yet ready for prime time in axial spondyloarthritis,” Atul Deodhar, MDMRCP, of Oregon Health and Science University, told attendees at the Congress of Clinical Rheumatology West. “However, aggressive therapy is still important.”
Whether treating axial SpA or non-radiographic axial SpA,